Тевапаривит

Тевапаривит (paricalcitol) is an oral vitamin D analog prescribed to manage secondary hyperparathyroidism in chronic kidney disease. This medication helps regulate calcium and phosphate levels for patients on dialysis or with stage 3–5 CKD. Suitable for adults and children over 10 years.

Paricalcitol is used to treat secondary hyperparathyroidism in adults and children aged 10 and older with chronic kidney disease. It works by reducing elevated parathyroid hormone levels that can lead to bone and mineral disorders. Patients with CKD often experience imbalances in calcium and phosphate, which this medication helps correct. It is typically prescribed when standard vitamin D therapy is insufficient.

Paricalcitol helps restore balance to calcium and phosphate levels in the body, which may improve bone health and reduce symptoms associated with secondary hyperparathyroidism. Users may notice improved energy levels or reduced bone discomfort over time. Individual responses vary, and effects depend on adherence to the prescribed regimen.

Store Тевапаривит at room temperature away from moisture and heat. Keep the medication in its original container, tightly closed, and out of reach of children. Inform your healthcare provider about all current medications and medical conditions before starting this treatment. Regular blood tests may be required to monitor calcium, phosphate, and parathyroid hormone levels during therapy.

Paricalcitol may interact with other vitamin D supplements, calcium-based phosphate binders, or medications that affect calcium metabolism. Avoid taking additional vitamin D unless directed by a doctor. Certain antacids, diuretics, or corticosteroids may alter its effects. Always disclose all medications, including over-the-counter products, to your healthcare provider.